Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Liprotamase in CF-Related EPI (EASY)
NCT02823964Phase 4Completed
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Sep 2016
- Primary completion
- Mar 2018
- Modality
- Replacement Enzymes
- Countries
- 6
01
Overview
A Phase 4 trial of liprotamase in exocrine pancreatic insufficiency (EPI), sponsored by Anthera Pharmaceuticals, Inc.. Started Sep 2016; status: completed.
02
Drugs
liprotamase
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT02823964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02823964.